Immunogenicity is a major problem with protein-based therapeutics due to circulating anti-drug antibody (ADA) production. ADA may lead to many clinical problems including allergic reactions, altered pharmacokinetic, reduced efficacy, etc. Thus, perform an immunogenicity testing to evaluate the ADA level induced by therapeutic protein drug is a necessary step in both clinical studies and post marketing clinical monitoring.